

Miguel Santin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6450689/publications.pdf>

Version: 2024-02-01

47
papers

2,127
citations

393982

19
h-index

243296

44
g-index

50
all docs

50
docs citations

50
times ranked

2005
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e178-e190.	4.6	51
2	Management of Drug Toxicity in <i>Mycobacterium avium</i> Complex Pulmonary Disease: An Expert Panel Survey. <i>Clinical Infectious Diseases</i> , 2021, 73, e256-e259.	2.9	16
3	Rifabutin for treating tuberculosis in solid organ transplant recipients: A retrospective observational study and literature review. <i>Transplant Infectious Disease</i> , 2021, 23, e13471.	0.7	4
4	Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on <i>Mycobacterium tuberculosis</i> . <i>Clinical Microbiology and Infection</i> , 2021, 27, 288.e1-288.e4.	2.8	9
5	Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 918.	1.0	15
6	Tuberculosis prevention in patients undergoing kidney transplantation: A nurse-led program for screening and treatment. <i>Transplant Infectious Disease</i> , 2021, 23, e13603.	0.7	3
7	Evaluation of the Fully Automated Chemiluminescence Analyzer Liaison XL for the Performance of the QuantiFERON-TB Gold Plus Assay in an Area with a Low Incidence of Tuberculosis. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0060321.	1.8	6
8	Editorial: Tuberculosis and Non-tuberculous Mycobacteria Infections: Control, Diagnosis and Treatment. <i>Frontiers in Public Health</i> , 2021, 9, 666187.	1.3	2
9	Identification of Recent Tuberculosis Exposure Using QuantiFERON-TB Gold Plus, a Multicenter Study. <i>Microbiology Spectrum</i> , 2021, 9, e0097221.	1.2	6
10	What is the role of the EUCAST reference method for MIC testing of the <i>Mycobacterium tuberculosis</i> complex?. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1453-1455.	2.8	14
11	Antimicrobial susceptibility testing of <i>Mycobacterium tuberculosis</i> complex isolates – the EUCAST broth microdilution reference method for MIC determination. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1488-1492.	2.8	49
12	Management of Tuberculosis: Are the Practices Homogeneous in High-Income Countries?. <i>Frontiers in Public Health</i> , 2020, 8, 443.	1.3	5
13	Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. <i>Clinical Infectious Diseases</i> , 2020, 71, 905-913.	2.9	357
14	Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. <i>European Respiratory Journal</i> , 2020, 56, 2000535.	3.1	336
15	Clinical Features Associated with Strongyloidiasis in Migrants and the Potential Impact of Immunosuppression: A Case Control Study. <i>Pathogens</i> , 2020, 9, 507.	1.2	8
16	Epidemic and pandemic viral infections: impact on tuberculosis and the lung. <i>European Respiratory Journal</i> , 2020, 56, 2001727.	3.1	89
17	Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. <i>Clinical Infectious Diseases</i> , 2020, 71, e1-e36.	2.9	367
18	High Prevalence of Strongyloidiasis in Spain: A Hospital-Based Study. <i>Pathogens</i> , 2020, 9, 107.	1.2	7

#	ARTICLE	IF	CITATIONS
19	Infectiousness of patients with smear-negative pulmonary tuberculosis, assessed by Real-time Polymerase Chain Reaction, Xpert [®] -MTB/RIF. <i>Journal of Infection</i> , 2020, 80, 298-300.	1.7	1
20	Tumor necrosis factor antagonists for paradoxical inflammatory reactions in the central nervous system tuberculosis. <i>Medicine (United States)</i> , 2020, 99, e22626.	0.4	14
21	Diagnosis and therapeutic approach of latent tuberculosis infection. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2018, 36, 302-311.	0.2	2
22	Diagnóstico y abordaje terapéutico de la infección tuberculosa latente. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018, 36, 302-311.	0.3	14
23	Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. <i>European Respiratory Journal</i> , 2018, 51, 1800170.	3.1	159
24	Reply to von Reyn and Horsburgh. <i>Clinical Infectious Diseases</i> , 2018, 67, 1308-1309.	2.9	1
25	Pulmonary Infections with Nontuberculous Mycobacteria, Catalonia, Spain, 1994-2014. <i>Emerging Infectious Diseases</i> , 2018, 24, 1091-1094.	2.0	28
26	Increasing isolation of rapidly growing mycobacteria in a low-incidence setting of environmental mycobacteria, 1994-2015. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 1425-1432.	1.3	22
27	QuantIFERON [®] -TB Gold In-Tube for contact screening in BCG-vaccinated adults: A longitudinal cohort study. <i>PLoS ONE</i> , 2017, 12, e0183258.	1.1	7
28	Prevention and Management of Tuberculosis in Transplant Recipients. <i>Transplantation</i> , 2016, 100, 1840-1852.	0.5	40
29	Executive summary of the guidelines for the use of interferon- γ release assays in the diagnosis of tuberculosis infection. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016, 34, 304-308.	0.3	10
30	Sumario ejecutivo de la guía de práctica clínica sobre el uso de las pruebas de liberación de interferón-gamma para el diagnóstico de infección tuberculosa. <i>Archivos De Bronconeumología</i> , 2016, 52, 477-481.	0.4	17
31	Detection of interleukin-2 is not useful for distinguishing between latent and active tuberculosis in clinical practice: a prospective cohort study. <i>Clinical Microbiology and Infection</i> , 2016, 22, 1007.e1-1007.e5.	2.8	5
32	Guidelines for the use of interferon- γ release assays in the diagnosis of tuberculosis infection. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016, 34, 303.e1-303.e13.	0.3	13
33	Linezolid for multidrug-resistant tuberculosis: How should we approach it?. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016, 34, 83-84.	0.3	2
34	Immunodiagnostic Tests [™] Predictive Values for Progression to Tuberculosis in Transplant Recipients. <i>Transplantation Direct</i> , 2015, 1, 1-5.	0.8	18
35	Prevention of Anti-Tumor Necrosis Factor-Associated Tuberculosis: A 10-Year Longitudinal Cohort Study. <i>Clinical Infectious Diseases</i> , 2015, 60, 349-356.	2.9	34
36	Interferon- γ Release Assays in Solid Organ Transplant Recipients: Everything Begins With a Single Small Step. <i>Clinical Infectious Diseases</i> , 2014, 58, 904-905.	2.9	1

#	ARTICLE	IF	CITATIONS
37	T-cell-based IFN- γ release assays for the diagnosis of latent tuberculosis infection: have they met our expectations?. <i>Expert Review of Molecular Diagnostics</i> , 2013, 13, 515-517.	1.5	3
38	Interferon- γ release assays versus tuberculin skin test for targeting people for tuberculosis preventive treatment: An evidence-based review. <i>Journal of Infection</i> , 2013, 66, 381-387.	1.7	32
39	Interferon- γ Release Assays for the Diagnosis of Tuberculosis and Tuberculosis Infection in HIV-Infected Adults: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2012, 7, e32482.	1.1	132
40	Detection of latent tuberculosis by the tuberculin skin test and a whole-blood interferon- γ release assay, and the development of active tuberculosis in HIV-seropositive persons. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 69, 59-65.	0.8	27
41	Comparison of the 2-step tuberculin skin test and the quantiFERON-TB gold in-tube test for the screening of tuberculosis infection before liver transplantation. <i>Liver Transplantation</i> , 2011, 17, 1205-1211.	1.3	44
42	Treatment completion in latent tuberculosis infection at specialist tuberculosis units in Spain. <i>International Journal of Tuberculosis and Lung Disease</i> , 2010, 14, 701-7.	0.6	21
43	Long-term relapses after 12-month treatment for <i>Mycobacterium kansasii</i> lung disease. <i>European Respiratory Journal</i> , 2009, 33, 148-152.	3.1	42
44	Impact of hepatitis C virus coinfection on immune restoration during successful antiretroviral therapy in chronic human immunodeficiency virus type 1 disease. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2007, 27, 65-73.	1.3	21
45	Comparative In Vitro Activities of Linezolid, Telithromycin, Clarithromycin, Levofloxacin, Moxifloxacin, and Four Conventional Antimycobacterial Drugs against <i>Mycobacterium kansasii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4562-4565.	1.4	48
46	<i>Mycobacterium kansasii</i> disease among patients infected with human immunodeficiency virus type 1: improved prognosis in the era of highly active antiretroviral therapy. <i>International Journal of Tuberculosis and Lung Disease</i> , 2003, 7, 673-7.	0.6	14
47	Hepatic and Pulmonary Pneumocystosis During Primary Prophylaxis for <i>Pneumocystis carinii</i> Pneumonia with Dapsone/Pyrimethamine. <i>Clinical Infectious Diseases</i> , 1993, 16, 171-171.	2.9	9